Why the study?
What is the clinical implication of the results of ALLHAT on clinical practice in treating patients with hypertension, and are their findings applicable to the local Chinese population?
What is the clinical implication of the results of ALLHAT on clinical practice in treating patients with hypertension, and are their findings applicable to the local Chinese population?
This editorial discusses the clinical implications of the ALLHAT trial results for hypertension management, particularly concerning their applicability to the Chinese population.
Hypertension is one of the most important preventable causes of premature death worldwide. Although lowering of blood pressure by anti- hypertensive agents have been shown to reduce morbidity and mortality in major clinical trials, the optimal antihypertensive agent remains unclear. The recently completed and published Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)1 was the largest trial of antihypertensive therapy ever conducted. ALLHAT is also the first clinical trial that designed to compare different antihypertensive agents for prevention of coronary heart disease (CHD) with the combined incidence of fatal CHD and non-fatal myocardial infarction as the primary endpoint. Since the publication of the results of ALLHAT, there has been intense debate across the medical community about its implications. What is the clinical implication of the results of ALLHAT on our clinical practice in treating patients with hypertension, and are their findings applicable to the local Chinese population?
No takes yet. Share an insight, caveat, or question.
Miu et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: